A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown promising results for treatment of relapsed or refractory acute ...
Nov 13, 2018
0
1
Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100 percent of early-stage colon cancers with mismatch repair deficiencies, ...
Oct 22, 2018
0
0
Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ...
Oct 22, 2018
0
5
Dr. Tasuku Honjo won the 2018 Nobel Prize in physiology or medicine for discovering the immune T-cell protein PD-1. This discovery led to a set of anti-cancer medications called checkpoint inhibitors, one of the first of ...
Oct 17, 2018
0
123
"You see this place on the image? That's where your kidney was," says VCU Massey Cancer Center medical oncologist Asit Paul, M.D., Ph.D., to 69-year-old Thomas Bland. "And the tumors we saw in your lung and other places still ...
Oct 2, 2018
0
12
(HealthDay)—For patients with previously untreated clear-cell advanced renal-cell carcinoma, nivolumab plus ipilimumab is associated with better overall survival than sunitinib, according to a study published online March ...
Mar 23, 2018
0
4
Some lung cancer patients in England can now be offered a potentially life-extending immunotherapy drug.
Sep 21, 2017
0
29
A new cooperative research study including Norris Cotton Cancer Center's Lionel Lewis, MB BCh, MD, finds that nivolumab plus ipilimumab therapy demonstrated manageable safety, notable antitumor activity, and durable responses ...
Jul 26, 2017
0
10
The immunotherapy nivolumab is kinder than chemotherapy for people with advanced head and neck cancer - easing many of the negative effects of the disease on patients' quality of life.
Jun 23, 2017
0
1
White blood cell counts can predict whether or not lung cancer patients will benefit from immunotherapy, according to research presented at the European Lung Cancer Conference (ELCC).
May 4, 2017
0
0
